Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

Richard A Furie, Eric F Morand, Ian N Bruce, Susan Manzi, Kenneth C Kalunian, Edward M Vital, Theresa Lawrence Ford, Ramesh Gupta, Falk Hiepe, Mittermayer Santiago, Philip Z Brohawn, Anna Berglind, Raj Tummala

Research output: Contribution to journalArticlepeer-review

3083 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry